Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Erich Platzer Biography and Net Worth

Director of Aptose Biosciences

Dr. Erich M. Platzer is a board-certified physician in internal medicine, hematology, and medical oncology. Previously, Dr. Platzer served as the business director of oncology, as well as the global strategic marketing and therapeutic area head of oncology at Roche, Basel. He was also the medical director in oncology and global development project leader and was responsible for various strategic corporate partnerships. Dr. Platzer is a director of Swiss Business Angel Groups, StartAngels, and BioBAC, and has served as a pharmaceutical industry expert on the board of directors of multiple biotech companies in both the U.S. and Europe such as Vivoryon, AOT, Léman Micro Devices, Credentis, and Viroblock. Dr. Platzer co-founded and currently serves as an investment advisor to HBM Healthcare Investments (formerly HBM BioVentures), a global leader in healthcare investing. He has over 12 years of experience in academic medicine and research and was a key member of the team at MSKCC that purified human G-CSF in 1983 (recombinant form: Neupogen®). He earned his Doctor of Medicine from the Medical School and the Institute of Clinical Immunology and Rheumatology of the University of Erlangen, where he also received his “Dr. med. habil.” (Doctor of Medicine and Doctor of Philosophy).

How do I contact Erich Platzer?: The corporate mailing address for Dr. Platzer and other Aptose Biosciences executives is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. Aptose Biosciences can also be reached via phone at 858-926-2730 and via email at [email protected]. Learn More on Erich Platzer's contact information.
Has Erich Platzer been buying or selling shares of Aptose Biosciences?: Erich Platzer has not been actively trading shares of Aptose Biosciences during the last ninety days. Most recently, on Wednesday, December 15th, Erich Platzer bought 18,000 shares of Aptose Biosciences stock. The stock was acquired at an average cost of $17.55 per share, with a total value of $315,900.00. Learn More on Erich Platzer's trading history.
Who are Aptose Biosciences' active insiders?: Aptose Biosciences' insider roster includes Rafael Bejar (VP), Denis Burger (Director), Erich Platzer (Director), William Rice (CEO), Warren Whitehead (Director), and Donald Wilson, Jr. (Major Shareholder). Learn More on Aptose Biosciences' active insiders.
Are insiders buying or selling shares of Aptose Biosciences?: In the last twelve months, Aptose Biosciences insiders bought shares 1 times. They purchased a total of 17,000 shares worth more than $53,380.00. The most recent insider tranaction occured on September, 22nd when Director Bernd R Seizinger bought 17,000 shares worth more than $53,380.00. Insiders at Aptose Biosciences own 9.5% of the company. Learn More about insider trades at Aptose Biosciences.
Information on this page was last updated on 9/22/2023.

Erich Platzer Insider Trading History at Aptose Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/15/2021	Buy	18,000	$17.55	$315,900.00
3/19/2019	Sell	1,333	$32.85	$43,789.05

Erich Platzer Buying and Selling Activity at Aptose Biosciences

Aptose Biosciences Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Today's Range

Now: $1.20

$1.16

$1.23

50 Day Range

MA: $1.56

$1.16

$1.95

2 Week Range

Now: $1.20

$1.15

$8.70

Volume

27,776 shs

Average Volume

86,397 shs

Market Capitalization

$18.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29